1 Sarah Fowler Res. Professor of Biostat. & Epi. Director, Biostatistics Center PhD in Mathematical Statistics Specialties: statistical design, conduct,

Slides:

Advertisements

Similar presentations

Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men Dariush Mozaffarian, M.D., Dr.P.H., Tao Hao, M.P.H., Eric B. Rimm, Sc.D., Walter.

Advertisements

The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011.

1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.

How do you approach a patient you think may have a PE?

National Diabetes Prevention Program Director, Division of Diabetes Translation Centers for Disease Control and Prevention National Center for Chronic.

Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.

Reducing the Risk of Developing Diabetes Chapter 5 Thomas Ransom, Ronald Goldenberg, Amanda Mikalachki, Ally PH Prebtani, Zubin Punthakee Canadian Diabetes.

Diabetes PREVENTION Lifestyle Change Program

Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.

Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.

Prevention of Type 2 Diabetes. Hyperglycemia in Type 2 Diabetes: Changing Treatment Paradigms.

SARC015: Phase II study of R1507 in wild-type GIST Margaret von Mehren, Fox Chase Cancer Center Katie Janeway, Dana Farber Cancer Institute.

Reducing the Risk of T2DM: What Works?

Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.

The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the CDC. Diabetes Prevention Ann.

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

2011 Diabetes Update Forum.  1) Be familiar with the evidence supporting the role of physical activity in the prevention of chronic disease  2) Develop.

Toujeo® and it’s Place in Therapy

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

4/26/001 Clinical Studies for Local Delivery of Nasal Aerosols and Sprays Izabela J. Roman, MD, PhD Founder & Medical Director Target Research Associates,

Intermountain Diabetes Prevention Program : Stepping Back to Move Forward Elizabeth Joy, MD, MPH Medical Director, Clinical Outcomes Research Family Medicine.

Lars Sjöström et al N Engl J Med 2004; 351: Characteristics of the Subjects at the Time of Matching and at the Time of the Inclusion Examination.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

Prevention of Diabetes Mellitus Prof. Adel El-Etriby Professor of Cardiology Ain Shams Faculty of Medicine.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Internet-based Telemedicine for Cardiovascular Disease Management Alfred A. Bove, MD, PhD Cardiology Section Temple University Medical Center.

Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.

Penn Mental Health AIDS Research Center Core F: Biostatistics and Data Management Core November 19 th, 2014 Core Director: Warren B. Bilker, Ph.D. Co-Director:

 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

© American Medical Association. All rights reserved. Modifications to any data or analysis provided requires either AMA written permission or the.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.

Diabetes Prevention Program (DPP)

A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.

Investigation 5-2 Did the prevention strategy work? xxxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx.

/ 161 Saudi Diploma in Family Medicine Center of Post Graduate Studies in Family Medicine EBM Therapy Articles Dr. Zekeriya Aktürk

CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.

1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.

Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Asad Mehdi, MD. Outline A Diagnostic Approach to Pulmonary Embolism Clinical Presentation Risk Stratification Wells Criteria Geneva Rule PIOPED Approach.

httpwww.youtube.com/watch?v=DhxD6sVQEYc:// The Drug Discovery Process.

Pulmonary Embolism in Patients with Unexplained Exacerbation of COPD: Prevalence and Risk Factors Isabelle Tillie-Leblond, MD, PhD; Charles-Hugo Marquette,

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

BETTER CARE THROUGH AN INTEGRATED PREVENTIve cARE NETWORK

Sample slides for your use

Making Diabetes Prevention a Reality: The National Diabetes Prevention Program Appalachian Diabetes Coalitions Celebrating Success Conference October.

Using Group Data to Treat Individuals: Understanding heterogeneous treatment effects in the age of precision medicine and patient centered care David M.

Section 4: Managing progression of CKD

Prediabetes: Targeting a population at risk

Clinical Trial Commentary

Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes.

The Evaluation of Suspected Pulmonary Embolism

Changing demographics and the impact on dementia

Macrovascular Complications Microvascular Complications

Sample slides for your use

Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.

EM. R1 박정숙.

Paul D. Stein, MD, Pamela K. Woodard, MD, John G. Weg, MD, Thomas W

EULAR Lupus Nephritis Trials Network Study Group

NIH’S Redefinition of Clinical Trials and Using the New Human Subjects Form Chris Sylvester, M.A. Senior Grant Administrator (AO) Grants and Contracts.

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Enrollment and Outcomes

Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.

Offer the National DPP lifestyle change program to your patient population Thank you for considering the National Diabetes Prevention Program lifestyle.

Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.

Presentation transcript:

1 Sarah Fowler Res. Professor of Biostat. & Epi. Director, Biostatistics Center PhD in Mathematical Statistics Specialties: statistical design, conduct, and analysis of multi- center clinical trials Funding: NIH/NIDDK,NHLBI

GWU Biostatistics Center Established 1972, Statistics Established 1972, Statistics Faculty affiliations in SPHHS/DEB Faculty affiliations in SPHHS/DEB Administratively in office of EVPAA Administratively in office of EVPAA 12 faculty, employees 12 faculty, employees Research awards to BSC investigators: $63 million/ year Research awards to BSC investigators: $63 million/ year 16 grants and contracts, duration 3 years – 40 years 16 grants and contracts, duration 3 years – 40 years

3 Diabetes Prevention Program Interventions to prevent/delay onset of Type II DM in 3234 subjects at high risk Interventions to prevent/delay onset of Type II DM in 3234 subjects at high risk Groups compared: lifestyle (ILS), metformin, and placebo Groups compared: lifestyle (ILS), metformin, and placebo Results: T he DPP Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: , Results: T he DPP Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: , Cohort being followed for 10 years, ending in 2012 Cohort being followed for 10 years, ending in 2012

4 Results of the DPP 158,000 screened, 3819 enrolled PlaceboMetformin Life-style Incidence of diabetes 11.0% 7.8% 4.8% (percent per year) (percent per year) Reduction in incidence % 58% compared with placebo compared with placebo Number needed to treat to prevent 1 case in 3 yrs to prevent 1 case in 3 yrs Results are similar across ethnic groups Results are similar across ethnic groups

5 Pulmonary Embolism Diagnosis PIOPED II: diagnostic accuracy of multi-detector spiral CT angiography/venography PIOPED II: diagnostic accuracy of multi-detector spiral CT angiography/venography 773 patients evaluated by CT and reference 773 patients evaluated by CT and reference Stein PD, et al. Multidetector Spiral CT For Acute Pulmonary Embolism: Results Of The PIOPED II Trial. N Engl J Med 2006; 354: Stein PD, et al. Multidetector Spiral CT For Acute Pulmonary Embolism: Results Of The PIOPED II Trial. N Engl J Med 2006; 354: ResultsSensitivitySpecificity CTA alone: 83%(76-92)96%(93-97) CTA/CTV:90%(84-93) 95%(92-96) CTA/CTV replaces more invasive tests PIOPED III: evaluating MR angiography/ venography (can be used in pregnant women and patients with renal disease) PIOPED III: evaluating MR angiography/ venography (can be used in pregnant women and patients with renal disease)